The EURORealTime SARS-CoV-2/Influenza A/B is a multiplex PCR-based test for fast and efficient detection and differentiation of SARSCoV- 2 and influenza viruses A and B from throat swabs. The assay aids discrimination between the clinically similar diseases COVID-19 and influenza, identification of potential co-infections and epidemiological surveillance.
The EURORealTime SARS-CoV-2/Influenza A/B incorporates reverse transcription and real-time PCR into one step, so that only one reaction is required per sample. This efficient combined testing saves time and resources, enabling more patient analyses to be performed per day and helping to conserve laboratory materials that are in short supply.
The detection of SARS-CoV-2 is based on two defined target sequences in the ORF1ab and N genes of the viral genome, ensuring high sensitivity. The variants alpha (B.1.1.7 lineage), beta (b.1.351 lineage), gamma (P.1 lineage) and delta (B1.617.2 lineage) can be reliably detected.
The detection of influenza viruses A and B – the two viruses responsible for flu outbreaks – is based on one defined target sequence from each virus.
The assay incorporates numerous controls, including an internal amplification control and a SARS-CoV-2/influenza A/B positive control, to ensure reliable results.
The assay is CE-marked and validated for all commonly used real-time PCR cyclers.
The complementary EURORealTime Analysis software provides fully automated and standardised evaluation and documentation of results, including all control results. Comprehensive automation options for sample preparation, PCR setup and PCR performance are available.